Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS):: Preliminary results of a phase I/II study.

被引：0
|
作者：
Vey, N
Dreyfus, F
Guerci, A
Fenaux, P
Dombret, H
Burnett, AK
Bosly, A
Feremans, W
Bowen, DT
Heiskala, M
机构：
[1] Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales
[2] Clin Univ Mt Godinne, Yvoir, Belgium
[3] Erasme Univ Hosp, Brussels, Belgium
[4] Ninewells Hosp, Dundee DD1 9SY, Scotland
[5] Celll Therapeut Inc, Clin, Seattle, WA USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1433
引用
收藏
页码：401A / 402A
页数：2
相关论文
共 50 条
  • [21] A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes
    de Castro, C.
    Adams, D.
    Rizzieri, D.
    Moore, J.
    Gockerman, J.
    Diehl, L.
    Horwitz, M.
    Edmonds, E.
    Warzecho, J.
    LEUKEMIA RESEARCH, 2009, 33 : S134 - S134
  • [22] Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Fenaux, Pierre
    Petrone, Michael E.
    Zbyszewski, Patrick Simon
    Fruchtman, Steven M.
    Silverman, Lewis R.
    BLOOD, 2016, 128 (22)
  • [23] Phase II study of amifostine in patients with myelodysplastic syndromes (MDS): Impact on hematopoiesis.
    List, AF
    Holmes, H
    Vempaty, H
    Greenberg, PL
    Bennett, JM
    BLOOD, 1998, 92 (10) : 714A - 714A
  • [24] A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)
    Navada, Shyamala C.
    Silverman, Lewis R.
    Hearn, Katherine P.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney
    Konopleva, Marina
    Borthakur, Gautam
    Pemmaraju, Naveen
    Kadia, Tapan
    Fenaux, Pierre
    Fruchtman, Steve
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [25] Phase II study of prolonged administration of arsenic trioxide (ATO) in patients with Myelodysplastic Syndromes (MDS) and Chronic myelomonocytic leukemia(CMML): M D Anderson Cancer Center experience
    Beran, Miloslav
    Verstovsek, Srdan
    Kornblau, Steven
    Estey, Elihu
    Giles, Francis
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    ANNALS OF ONCOLOGY, 2004, 15 : 157 - 157
  • [26] Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study
    Wesa, Kathleen M.
    Cunningham-Rundles, Susanna
    Klimek, Virginia M.
    Vertosick, Emily
    Coleton, Marci I.
    Yeung, K. Simon
    Lin, Hong
    Nimer, Stephen
    Cassileth, Barrie R.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (02) : 237 - 247
  • [27] Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study
    Kathleen M. Wesa
    Susanna Cunningham-Rundles
    Virginia M. Klimek
    Emily Vertosick
    Marci I. Coleton
    K. Simon Yeung
    Hong Lin
    Stephen Nimer
    Barrie R. Cassileth
    Cancer Immunology, Immunotherapy, 2015, 64 : 237 - 247
  • [28] Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes
    Uchida, Toshiki
    Ogawa, Yoshiaki
    Kobayashi, Yukio
    Ishikawa, Takayuki
    Ohashi, Haruhiko
    Hata, Tomoko
    Usui, Noriko
    Taniwaki, Masafumi
    Ohnishi, Kazunori
    Akiyama, Hideki
    Ozawa, Keiya
    Ohyashiki, Kazuma
    Okamoto, Shinichiro
    Tomita, Akihiro
    Nakao, Shinji
    Tobinai, Kensei
    Ogura, Michinori
    Ando, Kiyoshi
    Hotta, Tomomitsu
    CANCER SCIENCE, 2011, 102 (09) : 1680 - 1686
  • [29] Treatment with arsenic trioxide, ascorbic acid and dexamethasone in advanced myeloma patients: Preliminary findings of a multicenter, phase II study.
    Wu, K
    van Droogenbroeck, J
    Beksac, M
    de Knegt, Y
    Sonneveld, P
    BLOOD, 2005, 106 (11) : 367B - 367B
  • [30] Intensive treatment in patients with high risk myelodysplastic syndromes (MDS) and secondary acute leukemia (sAML). Preliminary study.
    Bargay, JJ
    Brunet, SS
    Esteve, JJ
    Ribera, JJ
    Llorente, AA
    Marti, JMJM
    Sarra, JJ
    Guardia, RR
    Pedro, CC
    Nomdedeu, BB
    Sierra, JJ
    Besalduch, JJ
    BLOOD, 2003, 102 (11) : 327B - 327B
12345